Oncology News Australia

Oncology News Australia Publishers of oncologynews.com.au, The Oncology Newsletter, and producers of The Oncology Podcast Welcome to the Oncology Network Australia!

We are a small group of academic publishing, communications and digital professionals building resources for the oncology profession. We aim to bring you quality, appropriate and independent digital resources through our suite of websites and publications. We are proud to support scientific advances that will improve patient outcomes and to fill some of the gaps created by Australia’s diverse and

challenging healthcare landscape. We hope to use our skills to support you by providing all the news you need in one innovative and easy-to-use place, as well as blogging and networking opportunities to advance our shared goals. We regularly work with a wide range of advertisers from a diverse range of specialities. These organisations include Pharmaceutical, Technology, Professional Development and Not-For-Profit organisations, (who we are able to offer significant discounts). We promote select products, services, resources, events, educational opportunities and positions vacant which are of active interest to and appropriate for our subscribers. If you seek to connect and present your product or service to this niche community you have come to the right place. Visit our advertising portal for more information.

Three new PBS oncology listings just dropped and they’re all about hitting the right target. Vorasidenib, selpercatinib,...
05/08/2026

Three new PBS oncology listings just dropped and they’re all about hitting the right target. Vorasidenib, selpercatinib, tafasitamab plus the key trial numbers and practical toxicity tips. Ready for a fast download? What’s most relevant to your clinic?

Check out The PBS Update: August 2026 episode

Listen on our website for Show Notes: https://oncologynetwork.com.au/pbs-update-august-2026/

Also available on Spotify, Apple Podcasts, YouTube etc

29/07/2026

🎙️ New Podcast | Managing Toxicity in the Era of Targeted Therapy

As targeted therapies continue to reshape the treatment landscape for intrahepatic cholangiocarcinoma (iCCA), clinicians are increasingly faced with a new challenge—recognising and managing the unique toxicities associated with these therapies.

In the second episode of our special Transforming iCCA podcast series, Associate Professor Jenny Liu is joined by internationally renowned iCCA expert Professor John Bridgewater to discuss practical, real-world approaches to toxicity management and why early molecular testing is critical for optimising patient outcomes.

🎧 In this episode, you'll hear about:
• How iCCA has evolved into a genomically stratified disease
• Why reflex molecular testing should occur as early as possible
• Practical strategies for managing FGFR inhibitor toxicities, including hyperphosphataemia, mucositis, nail and skin changes, ophthalmological effects and fatigue
• The role of multidisciplinary care in supporting patients on targeted therapies
• Resistance mechanisms, emerging therapies and how real-world outcomes compare with clinical trials

Whether you're already prescribing FGFR inhibitors or preparing for their increasing use in clinical practice, this episode offers valuable insights and practical take-home messages.

🎧 Listen now: t.ly/PoX5v | Access is free for healthcare professionals

NEW PODCAST: A new PBS listing can change a treatment plan overnight. In the latest podcast, we break down May 2026 onco...
13/05/2026

NEW PODCAST: A new PBS listing can change a treatment plan overnight. In the latest podcast, we break down May 2026 oncology and haematology updates: fruquintinib in mCRC, epcoritamab in DLBCL and CAR T in myeloma.

Join Professor Craig Underhill and Rachael Babin for a quick insightful update.

Listen here: https://oncologynetwork.com.au/pbs-update-may-2026/ or wherever you get your podcasts.

New PBS listing for third-line or later treatment of mCRC patients | Read more here... t.ly/5n391
01/05/2026

New PBS listing for third-line or later treatment of mCRC patients | Read more here... t.ly/5n391

Early molecular testing is changing what’s possible in cholangiocarcinoma🎙️ New episode: The Case for Early Molecular Te...
28/04/2026

Early molecular testing is changing what’s possible in cholangiocarcinoma

🎙️ New episode: The Case for Early Molecular Testing

We explore:
• Why up to 50% harbour actionable alterations
• The role of MDT care
• Practical challenges in tissue acquisition

HCPs can listen now 👇t.ly/RZWKz

25/04/2026

Listening material for the weekend? Check out the latest episode of The Oncology Journal Club - perfect listening for all healthcare professionals working in cancer care: Listen: t.ly/K8HIc

New episode of The Oncology Journal Club Podcast is out now 🎧 t.ly/a_hTMIn this instalment of The Oncology Journal Club,...
23/04/2026

New episode of The Oncology Journal Club Podcast is out now 🎧 t.ly/a_hTM

In this instalment of The Oncology Journal Club, we explore emerging evidence in intrahepatic cholangiocarcinoma (iCCA), genomic therapy matching and chrono-oncology.

From the NeoGOLP trial to national molecular screening efforts and treatment timing, the discussion goes beyond headline results to ask a critical question: what’s ready to influence practice—and what still needs more evidence?

What’s covered:
• NeoGOLP in high-risk resectable iCCA
• MoST programme and molecular matching
• Genomic therapy selection in practice
• Chrono-oncology and circadian biology
• CHOPIN trial in uveal melanoma
• ASCO living guideline updates

HCPs - listen on The Oncology Network for Show Notes with links to papers: t.ly/a_hTM

NEW PODCAST: Want a fast, practical PBS recap for Australian oncology practice? Hit play on The PBS Update April 2026 Up...
17/04/2026

NEW PODCAST: Want a fast, practical PBS recap for Australian oncology practice? Hit play on The PBS Update April 2026 Update https://oncologynetwork.com.au/pbs-update-april-2026/

Six new PBS cancer medicine listings in a month. What changed, who benefits and what should clinicians watch for with toxicity and testing? Listen for nuanced analysis from Professor Craig Underhill and tell us what surprised you most?

Also available on Spotify, Apple Podcasts, YouTube and where ever you get your podcasts!

Cholangiocarcinoma remains a challenging cancer to diagnose and treat — with many patients presenting at an advanced sta...
28/03/2026

Cholangiocarcinoma remains a challenging cancer to diagnose and treat — with many patients presenting at an advanced stage.

But with up to 40–50% of patients harbouring actionable mutations, earlier molecular testing is becoming increasingly important in shaping treatment pathways.

In our latest podcast episodes, Rachael Babin is joined by Professor Morteza Aghmesheh and Dr Chris Rogan to explore:
• Why early molecular profiling matters
• The role of multidisciplinary care
• Practical challenges in tissue acquisition
• How interventional radiology is expanding treatment options

A really insightful discussion on how better coordination — and earlier testing — could open up more opportunities for patients.

🎧 Listen here: https://oncologynetwork.com.au/the-multidisciplinary-management-of-cholangiocarcinoma/

Address

Surry Hills, NSW
2010

Alerts

Be the first to know and let us send you an email when Oncology News Australia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share